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T he etiology of heart failure (HF) has changed over time in more developed countries and is also evolving in less developed and other non-Western societies (1) (2) (3) (4) (5) (6) (7) (8) (9) . In the first report from the Framingham Heart Study, initiated in 1949 and published in 1971, hypertension was the most common etiology in patients recruited in the United States, although in that report HF was not subclassified by ejection fraction (EF) phenotype (1) . More recently, in most reports, coronary heart disease has become the predominant cause of HF with reduced EF (HFrEF) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . An epidemiologic transition has also occurred in Eastern Europe, Asia, and Africa from hypertension and rheumatic valvular disease to coronary heart disease (1-11).
Etiology is important for a number of reasons.
First, outcome may vary according to etiology with nonischemic causes purported to carry a better prognosis than HF of ischemic origin (12, 13) . Second, specific etiologies may be an indication for specific therapies (e.g., bypass surgery for coronary artery disease) (14) . Third, and more controversially, it has been suggested that the effectiveness of certain treatments for HFrEF may be modified by etiology (e.g., implantable cardiac defibrillator therapy in nonischemic cardiomyopathy and cardiac resynchronization therapy in ischemic compared with nonischemic HFrEF) (15, 16) . Table 1 ).
RESULTS

Of
Among the nonischemic etiologies, hypertensive etiology was most common in Latin America (21% of all cases of HFrEF) and least common in the Asia-Pacific Region (6%), whereas idiopathic etiology was most common in the Asia Pacific Region (28%) and least common in Central/Eastern Europe and North Values are mean AE SD, n (%), or median (interquartile range).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide; CABG ¼ coronary artery bypass graft; CRT ¼ cardiac resynchronization therapy; EF ¼ ejection fraction; HF ¼ heart failure; HR ¼ heart rate; ICD ¼ implantable cardioverter-defibrillator; NT-proBNP ¼ N terminalpro-B-type natriuretic peptide; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; SBP ¼ systolic blood pressure.
America (both 14%). However, because the numbers in some of these subgroups were small, these analyses may not be robust, and the apparent variation reported requires further investigation in other datasets. OUTCOMES ACCORDING TO ETIOLOGY. The rate of the primary composite outcome, its components and all-cause mortality are shown in Table 2 and Figure 1 .
Although, the rate of all of these events was highest in patients with an ischemic etiology, the adjusted HR was not different from patients in the 2 major nonischemic etiology categories (idiopathic and hypertensive). Repeating the analysis using any of history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, unstable angina, or angina to define the ischemic subgroup, instead of investigator-reported ischemic etiology, gave almost identical results (Online Table 2 ). Denmark. Overall, 1,924 (63%) of these patients had an LVEF <45%. Six major etiologic groups were identified by investigators: ischemic heart disease (n ¼ 925; 48.1%), idiopathic dilated cardiomyopathy (n ¼ 223; 11.6%), hypertension (n ¼ 204; 10.6%), valvular heart disease (n ¼ 165; 8.6%), other (n ¼ 183;
9.5%), and unknown/mixed (n ¼ 224; 11.6%). Our findings are broadly in keeping with these Danish data, although an ischemic etiology was more common, overall, and valvular etiology less frequent, in participants in PARADIGM-HF.
In keeping with prior reports, patients in PARADIGM-HF with an ischemic etiology had a higher crude incidence of adverse outcomes (12, 13, 25) . However, in contrast to previous findings, when adjusted for other prognostic variables, including we believe for the first time natriuretic peptides, outcomes in PARADIGM-HF did not differ by etiology (at least for the 3 largest categoriesdischemic, idiopathic, and hypertensive).
In the 2 earlier studies mentioned above, the multivariable models used adjusted for few variables and did not include natriuretic peptides in either case. Moreover, evidence-based life-saving therapies were not reported (Felker et al. [24] ) or underused (Pecini et al. [25] ) in the aforementioned studies, which were conducted before or at the beginning of the beta-blocker era in management of HFrEF.
Consequently, it would appear that in contemporary 
